{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:56:57Z","timestamp":1790769417112,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2022JJ30868"],"award-info":[{"award-number":["2022JJ30868"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2026JJ81334"],"award-info":[{"award-number":["2026JJ81334"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019091","name":"Key Research and Development Program of Hunan Province of China","doi-asserted-by":"publisher","award":["2026AQ2002"],"award-info":[{"award-number":["2026AQ2002"]}],"id":[{"id":"10.13039\/501100019091","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-026-05116-4","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:43:29Z","timestamp":1790329409000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumor cell membrane\u2011coated MOF\u2011199 nanoparticles co\u2011loaded with auranofin and celecoxib enhance single\u2011dose radiotherapy and anti\u2011PD\u2011L1 therapy in cervical cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Chenzhe","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0995-2254","authenticated-orcid":false,"given":"Yeqian","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"5116_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"5116_CR2","doi-asserted-by":"publisher","first-page":"705361","DOI":"10.3389\/fimmu.2021.705361","volume":"12","author":"M Zhu","year":"2021","unstructured":"Zhu M, Yang M, Zhang J, Yin Y, Fan X, Zhang Y, Qin S, Zhang H, Yu F. Immunogenic cell death induction by ionizing radiation. Front Immunol. 2021;12:705361.","journal-title":"Front Immunol"},{"key":"5116_CR3","doi-asserted-by":"crossref","unstructured":"Kim W, Lee S, Seo D, Kim D, Kim K, Kim E, Kang J, Seong KM, Youn H, Youn B. Cellular stress responses in radiotherapy. Cells. 2019;8(9):1105.","DOI":"10.3390\/cells8091105"},{"key":"5116_CR4","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","volume":"11","author":"J Fucikova","year":"2020","unstructured":"Fucikova J, Kepp O, Kasikova L, Petroni G, Yamazaki T, Liu P, Zhao L, Spisek R, Kroemer G, Galluzzi L. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 2020;11:1013.","journal-title":"Cell Death Dis"},{"key":"5116_CR5","doi-asserted-by":"crossref","unstructured":"Lamberti MJ, Nigro A, Mentucci FM, Rumie Vittar NB, Casolaro V, Dal Col J. Dendritic cells and immunogenic cancer cell death: A combination for improving antitumor immunity. Pharmaceut. 2020;12(3):256.","DOI":"10.3390\/pharmaceutics12030256"},{"key":"5116_CR6","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.gendis.2018.05.003","volume":"5","author":"YJ Wang","year":"2018","unstructured":"Wang YJ, Fletcher R, Yu J, Zhang L. Immunogenic effects of chemotherapy-induced tumor cell death. Genes Dis. 2018;5:194\u2013203.","journal-title":"Genes Dis"},{"key":"5116_CR7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.6004\/jnccn.2025.0057","volume":"23","author":"NR Abu-Rustum","year":"2025","unstructured":"Abu-Rustum NR, Campos SM, Amarnath S, Arend R, Barber E, Bradley K, Brooks R, Chino J, Chon HS, Crispens MA, et al. Cervical Cancer, Version 2.2026, NCCN Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2025;23:549\u201373.","journal-title":"J Natl Compr Canc Netw"},{"key":"5116_CR8","doi-asserted-by":"publisher","first-page":"984896","DOI":"10.3389\/fonc.2022.984896","volume":"12","author":"Y Xie","year":"2022","unstructured":"Xie Y, Kong W, Zhao X, Zhang H, Luo D, Chen S. Immune checkpoint inhibitors in cervical cancer: Current status and research progress. Front Oncol. 2022;12:984896.","journal-title":"Front Oncol"},{"key":"5116_CR9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3892\/ol.2026.15493","volume":"31","author":"X Zhou","year":"2026","unstructured":"Zhou X, An R, Li X. Cervical cancer immune microenvironment: Mechanisms of HPV-mediated immune evasion and advances in immunotherapy (Review). Oncol Lett. 2026;31:22.","journal-title":"Oncol Lett"},{"key":"5116_CR10","doi-asserted-by":"publisher","first-page":"754436","DOI":"10.3389\/fimmu.2021.754436","volume":"12","author":"E Appleton","year":"2021","unstructured":"Appleton E, Hassan J, Chan Wah Hak C, Sivamanoharan N, Wilkins A, Samson A, Ono M, Harrington KJ, Melcher A, Wennerberg E. Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade. Front Immunol. 2021;12:754436.","journal-title":"Front Immunol"},{"key":"5116_CR11","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","volume":"403","author":"D Lorusso","year":"2024","unstructured":"Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Sukhin V, Cloven N, Pereira de Santana Gomes AJ, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial. Lancet. 2024;403:1341\u201350.","journal-title":"Lancet"},{"key":"5116_CR12","doi-asserted-by":"publisher","first-page":"e35757","DOI":"10.1002\/cncr.35757","volume":"131","author":"LR Duska","year":"2025","unstructured":"Duska LR, Petroni GR, Thaker PH, Crane EK, Holman LL, Armstrong DK, Romano K, Scalici J. Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer. Cancer. 2025;131:e35757.","journal-title":"Cancer"},{"key":"5116_CR13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.7150\/ijbs.87867","volume":"20","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, Zhou Q, Zhao J, Hou X, Yan J, Sun X, Yang Z, Ma J, Zhang F, Zhan L, Hu K. Rebalancing TGF-\u03b2\/PGE(2) breaks RT-induced immunosuppressive barriers by enhancing tumor-infiltrated dendritic cell homing. Int J Biol Sci. 2024;20:367\u201386.","journal-title":"Int J Biol Sci"},{"key":"5116_CR14","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1172\/JCI16492","volume":"111","author":"L Yang","year":"2003","unstructured":"Yang L, Yamagata N, Yadav R, Brandon S, Courtney RL, Morrow JD, Shyr Y, Boothby M, Joyce S, Carbone DP, Breyer RM. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest. 2003;111:727\u201335.","journal-title":"J Clin Invest"},{"key":"5116_CR15","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1172\/JCI85339","volume":"126","author":"M Benhar","year":"2016","unstructured":"Benhar M, Shytaj IL, Stamler JS, Savarino A. Dual targeting of the thioredoxin and glutathione systems in cancer and HIV. J Clin Invest. 2016;126:1630\u20139.","journal-title":"J Clin Invest"},{"key":"5116_CR16","doi-asserted-by":"publisher","first-page":"e2249948","DOI":"10.1002\/eji.202249948","volume":"53","author":"J Muri","year":"2023","unstructured":"Muri J, Kopf M. The thioredoxin system: Balancing redox responses in immune cells and tumors. Eur J Immunol. 2023;53:e2249948.","journal-title":"Eur J Immunol"},{"key":"5116_CR17","doi-asserted-by":"publisher","first-page":"637504","DOI":"10.3389\/fonc.2021.637504","volume":"11","author":"D Pu","year":"2021","unstructured":"Pu D, Yin L, Huang L, Qin C, Zhou Y, Wu Q, Li Y, Zhou Q, Li L. Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer. Front Oncol. 2021;11:637504.","journal-title":"Front Oncol"},{"key":"5116_CR18","doi-asserted-by":"publisher","first-page":"35728","DOI":"10.18632\/oncotarget.16113","volume":"8","author":"H Wang","year":"2017","unstructured":"Wang H, Bouzakoura S, de Mey S, Jiang H, Law K, Dufait I, Corbet C, Verovski V, Gevaert T, Feron O, et al. Auranofin radiosensitizes tumor cells through targeting thioredoxin reductase and resulting overproduction of reactive oxygen species. Oncotarget. 2017;8:35728\u201342.","journal-title":"Oncotarget"},{"key":"5116_CR19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s12951-021-01074-1","volume":"19","author":"W Cao","year":"2021","unstructured":"Cao W, Jin M, Yang K, Chen B, Xiong M, Li X, Cao G. Fenton\/Fenton-like metal-based nanomaterials combine with oxidase for synergistic tumor therapy. J Nanobiotechnol. 2021;19:325.","journal-title":"J Nanobiotechnol"},{"key":"5116_CR20","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.ultsonch.2011.11.016","volume":"19","author":"AR Abbasi","year":"2012","unstructured":"Abbasi AR, Akhbari K, Morsali A. Dense coating of surface mounted CuBTC Metal-Organic Framework nanostructures on silk fibers, prepared by layer-by-layer method under ultrasound irradiation with antibacterial activity. Ultrason Sonochem. 2012;19:846\u201352.","journal-title":"Ultrason Sonochem"},{"key":"5116_CR21","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jcis.2020.12.028","volume":"587","author":"H Tian","year":"2021","unstructured":"Tian H, Zhang M, Jin G, Jiang Y, Luan Y. Cu-MOF chemodynamic nanoplatform via modulating glutathione and H(2)O(2) in tumor microenvironment for amplified cancer therapy. J Colloid Interface Sci. 2021;587:358\u201366.","journal-title":"J Colloid Interface Sci"},{"key":"5116_CR22","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s12951-026-04171-1","volume":"24","author":"B Liu","year":"2026","unstructured":"Liu B, Kong W, Zhang X, Ren B, Cheng Y, Su Y, Wang R, Feng Y, Zhou W. Targeting redox metabolism and low-dose radiotherapy synergistically activate cGAS-STING pathway to improve NK cell therapy efficacy in hepatocellular carcinoma. J Nanobiotechnol. 2026;24:295.","journal-title":"J Nanobiotechnol"},{"key":"5116_CR23","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1021\/jacs.5b11720","volume":"138","author":"H Zheng","year":"2016","unstructured":"Zheng H, Zhang Y, Liu L, Wan W, Guo P, Nystr\u00f6m AM, Zou X. One-pot Synthesis of Metal-Organic Frameworks with Encapsulated Target Molecules and Their Applications for Controlled Drug Delivery. J Am Chem Soc. 2016;138:962\u20138.","journal-title":"J Am Chem Soc"},{"key":"5116_CR24","doi-asserted-by":"publisher","first-page":"e2306031","DOI":"10.1002\/advs.202306031","volume":"11","author":"C Du","year":"2024","unstructured":"Du C, Guo X, Qiu X, Jiang W, Wang X, An H, Wang J, Luo Y, Du Q, Wang R, et al. Self-Reinforced Bimetallic Mito-Jammer for Ca(2+) Overload-Mediated Cascade Mitochondrial Damage for Cancer Cuproptosis Sensitization. Adv Sci (Weinh). 2024;11:e2306031.","journal-title":"Adv Sci (Weinh)"},{"key":"5116_CR25","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1039\/D3TB02929H","volume":"12","author":"L Yang","year":"2024","unstructured":"Yang L, Wang K, Guo L, Hu X, Zhou M. Unveiling the potential of HKUST-1: synthesis, activation, advantages and biomedical applications. J Mater Chem B. 2024;12:2670\u201390.","journal-title":"J Mater Chem B"},{"key":"5116_CR26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12951-022-01250-x","volume":"20","author":"S Zhuang","year":"2022","unstructured":"Zhuang S, Xiang H, Chen Y, Wang L, Chen Y, Zhang J. Engineering 2D Cu-composed metal-organic framework nanosheets for augmented nanocatalytic tumor therapy. J Nanobiotechnol. 2022;20:66.","journal-title":"J Nanobiotechnol"},{"key":"5116_CR27","doi-asserted-by":"publisher","first-page":"102742","DOI":"10.1016\/j.jbc.2022.102742","volume":"299","author":"B Li","year":"2023","unstructured":"Li B, Yao X, Li J, Lu X, Zhang W, Duan W, Tian Y, Li D. A tumor microenvironment-activated metal-organic framework-based nanoplatform for amplified oxidative stress-induced enhanced chemotherapy. J Biol Chem. 2023;299:102742.","journal-title":"J Biol Chem"},{"key":"5116_CR28","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1021\/nl500618u","volume":"14","author":"RH Fang","year":"2014","unstructured":"Fang RH, Hu CM, Luk BT, Gao W, Copp JA, Tai Y, O\u2019Connor DE, Zhang L. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett. 2014;14:2181\u20138.","journal-title":"Nano Lett"},{"key":"5116_CR29","doi-asserted-by":"publisher","first-page":"5726","DOI":"10.1038\/s41467-021-26052-x","volume":"12","author":"L Liu","year":"2021","unstructured":"Liu L, Bai X, Martikainen MV, K\u00e5rlund A, Roponen M, Xu W, Hu G, Tasciotti E, Lehto VP. Cell membrane coating integrity affects the internalization mechanism of biomimetic nanoparticles. Nat Commun. 2021;12:5726.","journal-title":"Nat Commun"},{"key":"5116_CR30","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","volume":"12","author":"FG Herrera","year":"2022","unstructured":"Herrera FG, Ronet C, Ochoa de Olza M, Barras D, Crespo I, Andreatta M, Corria-Osorio J, Spill A, Benedetti F, Genolet R, et al. Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. Cancer Discov. 2022;12:108\u201333.","journal-title":"Cancer Discov"},{"key":"5116_CR31","doi-asserted-by":"publisher","first-page":"1074477","DOI":"10.3389\/fimmu.2022.1074477","volume":"13","author":"S Zhu","year":"2022","unstructured":"Zhu S, Wang Y, Tang J, Cao M. Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment. Front Immunol. 2022;13:1074477.","journal-title":"Front Immunol"},{"key":"5116_CR32","doi-asserted-by":"crossref","unstructured":"Patel RB, Hernandez R, Carlson P, Grudzinski J, Bates AM, Jagodinsky JC, Erbe A, Marsh IR, Arthur I, Aluicio-Sarduy E et al. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade. Sci Transl Med. 2021;13(602):eabb3631.","DOI":"10.1126\/scitranslmed.abb3631"},{"key":"5116_CR33","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4149\/gpb_2016043","volume":"36","author":"H Hwang-Bo","year":"2017","unstructured":"Hwang-Bo H, Jeong JW, Han MH, Park C, Hong SH, Kim GY, Moon SK, Cheong J, Kim WJ, Yoo YH, Choi YH. Auranofin, an inhibitor of thioredoxin reductase, induces apoptosis in hepatocellular carcinoma Hep3B cells by generation of reactive oxygen species. Gen Physiol Biophys. 2017;36:117\u201328.","journal-title":"Gen Physiol Biophys"},{"key":"5116_CR34","doi-asserted-by":"publisher","first-page":"1247268","DOI":"10.3389\/fimmu.2023.1247268","volume":"14","author":"Z Zheng","year":"2023","unstructured":"Zheng Z, Su J, Bao X, Wang H, Bian C, Zhao Q, Jiang X. Mechanisms and applications of radiation-induced oxidative stress in regulating cancer immunotherapy. Front Immunol. 2023;14:1247268.","journal-title":"Front Immunol"},{"key":"5116_CR35","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/leu.2010.6","volume":"24","author":"LJ Mah","year":"2010","unstructured":"Mah LJ, El-Osta A, Karagiannis TC. gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia. 2010;24:679\u201386.","journal-title":"Leukemia"},{"key":"5116_CR36","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.3390\/pharmaceutics14081564","volume":"14","author":"MC Rodrigues","year":"2022","unstructured":"Rodrigues MC, Morais JAV, Ganassin R, Oliveira GRT, Costa FC, Morais AAC, Silveira AP, Silva VCM, Longo JPF, Muehlmann LA. An Overview on Immunogenic Cell Death in Cancer Biology and Therapy. Pharmaceutics. 2022;14:1564.","journal-title":"Pharmaceutics"},{"key":"5116_CR37","first-page":"1368","volume":"12","author":"A Kobayashi","year":"2023","unstructured":"Kobayashi A, Hiroyama Y, Mamiya T, Oikawa M, Konishi T. The COX-2\/PGE2 Response Pathway Upregulates Radioresistance in A549 Human Lung Cancer Cells through Radiation-Induced Bystander Signaling. Biology (Basel). 2023;12:1368.","journal-title":"Biology (Basel)"},{"key":"5116_CR38","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.intimp.2014.08.024","volume":"23","author":"XY Jia","year":"2014","unstructured":"Jia XY, Chang Y, Sun XJ, Dai X, Wei W. The role of prostaglandin E2 receptor signaling of dendritic cells in rheumatoid arthritis. Int Immunopharmacol. 2014;23:163\u20139.","journal-title":"Int Immunopharmacol"},{"key":"5116_CR39","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13:54\u201361.","journal-title":"Nat Med"},{"key":"5116_CR40","doi-asserted-by":"publisher","first-page":"e24568","DOI":"10.4161\/onci.24568","volume":"2","author":"Y Ma","year":"2013","unstructured":"Ma Y, Adjemian S, Yang H, Catani JP, Hannani D, Martins I, Michaud M, Kepp O, Sukkurwala AQ, Vacchelli E, et al. ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. Oncoimmunology. 2013;2:e24568.","journal-title":"Oncoimmunology"},{"key":"5116_CR41","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","volume":"13","author":"L Apetoh","year":"2007","unstructured":"Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050\u20139.","journal-title":"Nat Med"},{"key":"5116_CR42","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","volume":"49","author":"CS Garris","year":"2018","unstructured":"Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, et al. Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-\u03b3 and IL-12. Immunity. 2018;49:1148\u2013e11611147.","journal-title":"Immunity"},{"key":"5116_CR43","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1126\/science.aaf1292","volume":"355","author":"E Hui","year":"2017","unstructured":"Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, Sasmal DK, Huang J, Kim JM, Mellman I, Vale RD. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017;355:1428\u201333.","journal-title":"Science"},{"key":"5116_CR44","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1002\/eji.1830270526","volume":"27","author":"T De Smedt","year":"1997","unstructured":"De Smedt T, Van Mechelen M, De Becker G, Urbain J, Leo O, Moser M. Effect of interleukin-10 on dendritic cell maturation and function. Eur J Immunol. 1997;27:1229\u201335.","journal-title":"Eur J Immunol"},{"key":"5116_CR45","doi-asserted-by":"publisher","first-page":"7520","DOI":"10.1158\/0008-5472.CAN-08-1060","volume":"68","author":"M Ahmadi","year":"2008","unstructured":"Ahmadi M, Emery DC, Morgan DJ. Prevention of both direct and cross-priming of antitumor CD8\u2009+\u2009T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo. Cancer Res. 2008;68:7520\u20139.","journal-title":"Cancer Res"},{"key":"5116_CR46","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3390\/pharmaceutics12030256","volume":"12","author":"MJ Lamberti","year":"2020","unstructured":"Lamberti MJ, Nigro A, Mentucci FM, Rumie Vittar NB, Casolaro V, Dal Col J. Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity. Pharmaceutics. 2020;12:256.","journal-title":"Pharmaceutics"},{"key":"5116_CR47","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.drudis.2021.01.002","volume":"26","author":"S Kumar","year":"2021","unstructured":"Kumar S, Singh SK, Rana B, Rana A. Tumor-infiltrating CD8(+) T cell antitumor efficacy and exhaustion: molecular insights. Drug Discov Today. 2021;26:951\u201367.","journal-title":"Drug Discov Today"},{"key":"5116_CR48","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41586-024-07254-x","volume":"629","author":"SB Lacher","year":"2024","unstructured":"Lacher SB, D\u00f6rr J, de Almeida GP, H\u00f6nninger J, Bayerl F, Hirschberger A, Pedde AM, Meiser P, Ramsauer L, Rudolph TJ, et al. PGE(2) limits effector expansion of tumour-infiltrating stem-like CD8(+) T cells. Nature. 2024;629:417\u201325.","journal-title":"Nature"},{"key":"5116_CR49","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.3390\/cells10113104","volume":"10","author":"A Guti\u00e9rrez-Hoya","year":"2021","unstructured":"Guti\u00e9rrez-Hoya A, Soto-Cruz I. NK Cell Regulation in Cervical Cancer and Strategies for Immunotherapy. Cells. 2021;10:3104.","journal-title":"Cells"},{"key":"5116_CR50","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0014-5793(04)00026-2","volume":"559","author":"RS Alli","year":"2004","unstructured":"Alli RS, Khar A. Interleukin-12 secreted by mature dendritic cells mediates activation of NK cell function. FEBS Lett. 2004;559:71\u20136.","journal-title":"FEBS Lett"},{"key":"5116_CR51","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1245\/ASO.2003.08.017","volume":"10","author":"I Yakar","year":"2003","unstructured":"Yakar I, Melamed R, Shakhar G, Shakhar K, Rosenne E, Abudarham N, Page GG, Ben-Eliyahu S. Prostaglandin e(2) suppresses NK activity in vivo and promotes postoperative tumor metastasis in rats. Ann Surg Oncol. 2003;10:469\u201379.","journal-title":"Ann Surg Oncol"},{"key":"5116_CR52","doi-asserted-by":"publisher","first-page":"e000867","DOI":"10.1136\/jitc-2020-000867","volume":"8","author":"ZS Buchwald","year":"2020","unstructured":"Buchwald ZS, Nasti TH, Lee J, Eberhardt CS, Wieland A, Im SJ, Lawson D, Curran W, Ahmed R, Khan MK. Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy. J Immunother Cancer. 2020;8:e000867.","journal-title":"J Immunother Cancer"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-05116-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-05116-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-05116-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:10:49Z","timestamp":1790766649000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-05116-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5116"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-05116-4","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"28 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"916"}}